X
Record #69611

Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar

Journal
PLoS One
Publisher
PLoS
Original paper date
Nov 15, 2022
Institution
Department of Gastroenterology and Hepatology, Erasmus MC Medical Center, Rotterdam, The Netherlands · Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands · Julius Clinical, Zeist, The Netherlands · Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands · Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands · Montreal Heart Institute Coordinating Center, Université de Montréal, Montreal, Canada · Department of Cardiovascular Medicine, Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland, OH, United States of America · Division of Cardiology, VA Medical Center and University of Colorado School of Medicine, Denver, CO, United States of America · Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands · Department of Endocrinology, Erasmus MC Medical Center, Rotterdam, The Netherlands
Open access
No
Article type
Clinical Study
Broad categories
(HSC) Medicine - Cardiovascular(HSC) Medicine - Diabetes(HSC) Medicine - Gastroenterology(HSC) Medicine - Pharmacology
Citation lifecycle

How this paper is being cited

Pre-retraction
10
Same day
0
Post-retraction
0
% post-retraction
0.0%
~3.2 citations/yr before retraction · ~0.0 citations/yr after
— citing papers

Who is still citing this work

Loading…
Back to browse